meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - adjuvant
13
antibody–drug conjugate
trastuzumab emtansine
trastuzumab emtasine plus endocrine therapy
cyclin inhibitor
abemaciclib based treatment
abemaciclib plus endocrine therapy
palbociclib based treatment
palbociclib
palbociclib plus endocrine therapy
HER inhibitor
HER2 inhibitor
neratinib based treatment
neratinib
pertuzumab based treatment
pertuzumab plus trastuzumab
trastuzumab based treatment
docetaxel plus carboplatin with trastuzumab followed by trastuzumab
doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone
mTOR inhibitors
everolimus
poly ADP-ribose polymerase (PARP) inhibitor
olaparib
versus all
vs chemotherapy
vs doxorubicin plus cyclophosphamide followed by docetaxel
vs endocrine therapy
vs HER inhibitor
vs HER2 inhibitor
vs trastuzumab based treatment
vs docetaxel plus carboplatin with trastuzumab followed by trastuzumab
vs trastuzumab
vs non active control
vs placebo
All patients
HER2 positive
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
iDFS
RFS/DFS
Statistically conclusive or suggested result
Inconclusive results
Uncertain results
Safety results
breast cancer - adjuvant
breast cancer - adjuvant
versus placebo
neratinib vs. placebo
1
none
-
-
-
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open